Regency Centers is a preeminent national owner, operator, and developer of shopping centers located in suburban trade areas with compelling demographics. Our portfolio includes thriving properties merchandised with highly productive grocers, restaurants, service providers, and best-in-class retailers that connect to their neighborhoods, communities, and customers. Operating as a fully integrated real estate company, Regency Centers is a qualified real estate investment trust (REIT) that is self-administered, self-managed, and an S&P 500 Index member.

Regency Centers Corporation

RBC Capital analyst Craig Wong-Pan maintained a Buy rating on Regis Healthcare Ltd. on July 16 and set a price target of A$7.50. The company’s shar...

RBC Capital Keeps Their Buy Rating on Regis Healthcare Ltd. (REG)

In a report released today, Vanessa Thomson from Jefferies maintained a Buy rating on Regis Healthcare Ltd., with a price target of A$8.00. Accordi...

Regis Healthcare Ltd. (REG) Gets a Buy from Jefferies

Regis Healthcare Ltd. ( ($AU:REG) ) just unveiled an update. Regis Healthcare has announced the retirement of Chief Financial Officer Rick Rostolis...

Regis Healthcare CFO Rick Rostolis to Retire After Guiding Growth and M&A Strategy

UBS analyst David Low maintained a Hold rating on Regis Healthcare Ltd. today and set a price target of A$7.00. According to TipRanks, Low is a 3-s...

Regis Healthcare Ltd. (REG) Gets a Hold from UBS

RemeGen Co. Ltd. Class H ( ($HK:9995) ) has shared an update. RemeGen Co., Ltd., a Hong Kong-listed Chinese biopharmaceutical company, is leveragin...

RemeGen Deploys Idle Funds Into SPDB Wealth Products in Discloseable Transaction

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alumis Inc. (ALMS), Glaukos (GKOS) and Regeneron (...

Analysts Conflicted on These Healthcare Names: Alumis Inc. (ALMS), Glaukos (GKOS) and Regeneron (REGN)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Targets Fatty Liver Disease With New Phase 2a Stud...

Regeneron Expands Metabolic Footprint With New Phase 2a Fatty Liver Study

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals, Inc. (REGN) is running a first-in...

Regeneron’s New First-in-Human Eczema Drug REGN20423: Early Trial Progress and Investor Takeaways

The latest update is out from Regis Healthcare Ltd. ( ($AU:REG) ). Regis Healthcare Limited has issued 17,085 new performance rights under its empl...

Regis Healthcare Issues New Unquoted Performance Rights Under Staff Incentive Plan

Smart Powerr Corp ( ($CREG) ) just unveiled an announcement. On June 15, 2026, Smart Powerr Corp. implemented a 1-for-10 reverse stock split of its...

Smart Powerr Corp Implements 1-for-10 Reverse Split

Regis Healthcare Ltd. ( ($AU:REG) ) has shared an update. Regis Healthcare Limited has reported the cessation of 782,814 performance rights, which ...

Regis Healthcare reports lapse of performance rights and updates capital structure

Jarden analyst Steven Wheen downgraded Regis Healthcare Ltd. to a Hold on June 18 and set a price target of A$7.50. The company’s shares closed las...

Jarden downgrades Regis Healthcare Ltd. (REG) to a Hold

Regis Healthcare Ltd. ( ($AU:REG) ) has provided an update. Regis Healthcare has announced that director Linda Jane Mellors ceased to be a director...

Regis Healthcare Discloses Final Director Interest as Linda Mellors Exits Board

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. The study titled “A FIH Phase 1/2 Study to Assess Safety, To...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REG	$82.68	+0.36%	1.44M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REG	$82.68	+0.4%	1.44M
3
4
5
6

REG

REG

Get Regency Centers Corporation Data in Excel

Get Regency Centers Corporation Data in Excel